Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 6
2004 1
2005 5
2006 3
2007 5
2008 11
2009 8
2010 19
2011 11
2012 26
2013 28
2014 21
2015 25
2016 26
2017 26
2018 31
2019 34
2020 34
2021 40
2022 42
2023 29
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

397 results

Results by year

Filters applied: . Clear all
Page 1
Correction: Mapping study for health emergency and disaster risk management competencies and curricula: literature review and cross-sectional survey.
Hung KKC, MacDermot MK, Hui TSI, Chan SY, Mashino S, Mok CPY, Leung PH, Kayano R, Abrahams J, Wong CS, Chan EYY, Graham CA. Hung KKC, et al. Among authors: chan eyy. Global Health. 2024 Apr 12;20(1):30. doi: 10.1186/s12992-024-01037-9. Global Health. 2024. PMID: 38610014 Free PMC article. No abstract available.
Development of CD46 targeted alpha theranostics in prostate cancer using 134Ce/225Ac-Macropa-PEG4-YS5.
Bobba KN, Bidkar AP, Wadhwa A, Meher N, Drona S, Sorlin AM, Bidlingmaier S, Zhang L, Wilson DM, Chan E, Greenland NY, Aggarwal R, VanBrocklin HF, He J, Chou J, Seo Y, Liu B, Flavell RR. Bobba KN, et al. Among authors: chan e. Theranostics. 2024 Jan 27;14(4):1344-1360. doi: 10.7150/thno.92742. eCollection 2024. Theranostics. 2024. PMID: 38389832 Free PMC article.
Long-term risk prediction after major lower limb amputation: 1-year results of the PERCEIVE study.
Gwilym BL, Pallmann P, Waldron CA, Thomas-Jones E, Milosevic S, Brookes-Howell L, Harris D, Massey I, Burton J, Stewart P, Samuel K, Jones S, Cox D, Clothier A, Prout H, Edwards A, Twine CP, Bosanquet DC; Vascular and Endovascular Research Network (VERN) and the PERCEIVE study group. Gwilym BL, et al. BJS Open. 2024 Jan 3;8(1):zrad135. doi: 10.1093/bjsopen/zrad135. BJS Open. 2024. PMID: 38266124 Free PMC article.
PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models.
Berlin M, Cantley J, Bookbinder M, Bortolon E, Broccatelli F, Cadelina G, Chan EW, Chen H, Chen X, Cheng Y, Cheung TK, Davenport K, DiNicola D, Gordon D, Hamman BD, Harbin A, Haskell R, He M, Hole AJ, Januario T, Kerry PS, Koenig SG, Li L, Merchant M, Pérez-Dorado I, Pizzano J, Quinn C, Rose CM, Rousseau E, Soto L, Staben LR, Sun H, Tian Q, Wang J, Wang W, Ye CS, Ye X, Zhang P, Zhou Y, Yauch R, Dragovich PS. Berlin M, et al. Among authors: chan ew. J Med Chem. 2024 Jan 25;67(2):1262-1313. doi: 10.1021/acs.jmedchem.3c01781. Epub 2024 Jan 5. J Med Chem. 2024. PMID: 38180485
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial.
Kuboki Y, Fakih M, Strickler J, Yaeger R, Masuishi T, Kim EJ, Bestvina CM, Kopetz S, Falchook GS, Langer C, Krauss J, Puri S, Cardona P, Chan E, Varrieur T, Mukundan L, Anderson A, Tran Q, Hong DS. Kuboki Y, et al. Among authors: chan e. Nat Med. 2024 Jan;30(1):265-270. doi: 10.1038/s41591-023-02717-6. Epub 2024 Jan 4. Nat Med. 2024. PMID: 38177853 Clinical Trial.
Diagnosis and management of neuroendocrine prostate cancer.
de Kouchkovsky I, Chan E, Schloss C, Poehlein C, Aggarwal R. de Kouchkovsky I, et al. Among authors: chan e. Prostate. 2024 Apr;84(5):426-440. doi: 10.1002/pros.24664. Epub 2024 Jan 3. Prostate. 2024. PMID: 38173302 Review.
397 results